在FDA关键试验中的心力衰竭终点
Mori J Krantz1, Fortunato Senatore1, Mitchell A Psotka1,2
1Division of Cardiology and Nephrology (DCN), Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN), Office of New Drugs, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA).
European heart journal
|January 30, 2026
概括
需要新的心力衰竭 (HF) 试验设计来评估患者报告的结果和门诊事件. 这种方法可以提高试验的效率,并证明新型HF疗法的公共健康益处.
科学领域:
- 心脏病学 心脏病学
- 临床试验 临床试验
- 监管科学 监管科学
背景情况:
- 传统的心力衰竭 (HF) 药物批准的重点是减少心血管死亡和住院治疗.
- 有效的HF疗法已经减少了这些艰难的结果,需要新的试验终点.
- 改变急性HF管理的临床实践需要更新的试验设计.
研究的目的:
- 提出对创新高频试验的当代监管视角.
- 为了标准化和简化心力衰竭治疗的临床试验.
- 探索将患者报告的结果和门诊事件纳入HF试验终点.
主要方法:
- 对HF试验的当前监管指南的审查.
- 对HF护理提供不断变化的环境进行分析.
- 考虑捕捉患者功能和门诊事件的新型终点.
主要成果:
- 硬结局的逐渐减少需要替代试验终点.
- 门诊事件,从住院相当于小的护理变化,对终点标准化提出挑战.
- 患者报告的结果和特定的门诊事件具有吸引力,可以在更小,更短的试验中证明有效性.
结论:
- 通过将患者报告的结果和相关的门诊事件纳入HF试验设计的创新,可以提高效率.
- 标准化终点对于确保新型HF疗法的明确公共卫生益处至关重要.
- 将试验方法与当前的临床实践相适应,对于推进心力衰竭治疗至关重要.
相关概念视频
Heart Failure II: Pathophysiology
907
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
907
Pathophysiology of Heart Failure
3.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.6K
Heart Failure I: Introduction
877
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
877
Heart Failure VI: Adjunct Therapies
332
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
332
Heart Failure Drugs: Diuretics
963
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
963
Heart Failure V: Medical Management
308
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
308


